EA202090718A1 - Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) - Google Patents
Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)Info
- Publication number
- EA202090718A1 EA202090718A1 EA202090718A EA202090718A EA202090718A1 EA 202090718 A1 EA202090718 A1 EA 202090718A1 EA 202090718 A EA202090718 A EA 202090718A EA 202090718 A EA202090718 A EA 202090718A EA 202090718 A1 EA202090718 A1 EA 202090718A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- antigen binding
- binding site
- binds
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Настоящее изобретение относится к мультиспецифическим связывающим белкам, которые связываются с опухолеассоциированным антигеном CLEC12A и с рецептором NKG2D и рецептором CD16 на естественных клетках-киллерах. Один аспект настоящего изобретения относится к белку, который включает первый антигенсвязывающий участок, который связывает NKG2D; второй антигенсвязывающий участок, который связывает CLEC12A; и Fc-домен антитела, его часть, достаточную для связывания CD16, или третий антигенсвязывающий участок, который связывает CD16. Каждый антигенсвязывающий участок может включать вариабельный домен тяжелой цепи антитела и вариабельный домен легкой цепи антитела, или один или более антигенсвязывающих участков могут представлять собой однодоменное антитело, такое как антитело VHH или антитело VNAR. Другой аспект настоящего изобретения относится к способу лечения рака у пациента. Способ включает введение пациенту терапевтически эффективного количества мультиспецифического связывающего белка.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762558510P | 2017-09-14 | 2017-09-14 | |
PCT/US2018/050916 WO2019055677A1 (en) | 2017-09-14 | 2018-09-13 | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090718A1 true EA202090718A1 (ru) | 2020-07-01 |
Family
ID=65723086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090718A EA202090718A1 (ru) | 2017-09-14 | 2018-09-13 | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200277384A1 (ru) |
EP (1) | EP3681532A4 (ru) |
JP (1) | JP2020534269A (ru) |
KR (1) | KR20200051789A (ru) |
CN (1) | CN111432832A (ru) |
AU (1) | AU2018331412A1 (ru) |
BR (1) | BR112020005078A2 (ru) |
CA (1) | CA3075857A1 (ru) |
EA (1) | EA202090718A1 (ru) |
IL (1) | IL273206A (ru) |
MA (1) | MA50255A (ru) |
MX (1) | MX2020002880A (ru) |
SG (1) | SG11202002298PA (ru) |
WO (1) | WO2019055677A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018148445A1 (en) | 2017-02-08 | 2018-08-16 | Adimab, Llc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
WO2019178364A2 (en) * | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
JP7453971B2 (ja) * | 2018-10-19 | 2024-03-21 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Nkエンゲージャー分子およびその使用方法 |
US20220119534A1 (en) * | 2020-05-06 | 2022-04-21 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and clec12a |
JP2024516645A (ja) * | 2021-04-26 | 2024-04-16 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | 抗clec12a抗体及びその使用 |
CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
CN117106086A (zh) * | 2022-08-09 | 2023-11-24 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
CN101945893B (zh) * | 2007-12-14 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 抗人nkg2d抗体及其用途 |
US10865233B2 (en) * | 2008-12-18 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | NKG2D-fc for immunotherapy |
US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
DK2900694T3 (en) * | 2012-09-27 | 2018-11-19 | Merus Nv | BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS |
ES2847155T3 (es) * | 2016-01-21 | 2021-08-02 | Novartis Ag | Moléculas multiespecíficas que fijan como objetivo CLL-1 |
CA3054738A1 (en) * | 2017-02-27 | 2018-08-30 | Dragonfly Therapeutics, Inc. | Multispecific binding proteins targeting cea |
-
2018
- 2018-09-13 JP JP2020514936A patent/JP2020534269A/ja active Pending
- 2018-09-13 WO PCT/US2018/050916 patent/WO2019055677A1/en active Application Filing
- 2018-09-13 BR BR112020005078-4A patent/BR112020005078A2/pt unknown
- 2018-09-13 EP EP18856132.8A patent/EP3681532A4/en active Pending
- 2018-09-13 CA CA3075857A patent/CA3075857A1/en active Pending
- 2018-09-13 EA EA202090718A patent/EA202090718A1/ru unknown
- 2018-09-13 US US16/645,613 patent/US20200277384A1/en active Pending
- 2018-09-13 KR KR1020207010605A patent/KR20200051789A/ko not_active Application Discontinuation
- 2018-09-13 CN CN201880072887.1A patent/CN111432832A/zh active Pending
- 2018-09-13 SG SG11202002298PA patent/SG11202002298PA/en unknown
- 2018-09-13 AU AU2018331412A patent/AU2018331412A1/en active Pending
- 2018-09-13 MA MA050255A patent/MA50255A/fr unknown
- 2018-09-13 MX MX2020002880A patent/MX2020002880A/es unknown
-
2020
- 2020-03-10 IL IL273206A patent/IL273206A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112020005078A2 (pt) | 2020-10-13 |
AU2018331412A1 (en) | 2020-03-26 |
EP3681532A4 (en) | 2021-09-01 |
CA3075857A1 (en) | 2019-03-21 |
EP3681532A1 (en) | 2020-07-22 |
CN111432832A (zh) | 2020-07-17 |
WO2019055677A1 (en) | 2019-03-21 |
IL273206A (en) | 2020-04-30 |
MX2020002880A (es) | 2020-10-01 |
US20200277384A1 (en) | 2020-09-03 |
KR20200051789A (ko) | 2020-05-13 |
MA50255A (fr) | 2021-05-26 |
JP2020534269A (ja) | 2020-11-26 |
SG11202002298PA (en) | 2020-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090718A1 (ru) | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) | |
WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
EA202090812A1 (ru) | Новые биспецифические полипептидные комплексы | |
EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
EA201691482A1 (ru) | Человеческие антитела к pd-1 | |
EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
EA201890296A1 (ru) | Pd-1-связывающие молекулы и способы их применения | |
EA202092417A1 (ru) | Химерные рецепторы к dll3 и способы их применения | |
EA201891066A1 (ru) | Антитела к ror1 | |
EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
EA201290570A1 (ru) | Конструкты, связывающиеся с ron, и способы их использования | |
EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
PE20221404A1 (es) | Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer | |
EA202190235A1 (ru) | Антитела к cd33 и способы их применения |